SG10201605325TA - P2x4 receptor antagonist - Google Patents
P2x4 receptor antagonistInfo
- Publication number
- SG10201605325TA SG10201605325TA SG10201605325TA SG10201605325TA SG10201605325TA SG 10201605325T A SG10201605325T A SG 10201605325TA SG 10201605325T A SG10201605325T A SG 10201605325TA SG 10201605325T A SG10201605325T A SG 10201605325TA SG 10201605325T A SG10201605325T A SG 10201605325TA
- Authority
- SG
- Singapore
- Prior art keywords
- receptor antagonist
- antagonist
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012005343 | 2012-01-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201605325TA true SG10201605325TA (en) | 2016-08-30 |
Family
ID=48781550
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201605325TA SG10201605325TA (en) | 2012-01-13 | 2013-01-10 | P2x4 receptor antagonist |
SG11201404030YA SG11201404030YA (en) | 2012-01-13 | 2013-01-10 | P2x4 receptor antagonist |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201404030YA SG11201404030YA (en) | 2012-01-13 | 2013-01-10 | P2x4 receptor antagonist |
Country Status (16)
Country | Link |
---|---|
US (5) | US9382236B2 (es) |
EP (1) | EP2803662B1 (es) |
JP (1) | JP6207399B2 (es) |
KR (2) | KR102140746B1 (es) |
CN (4) | CN108863959B (es) |
AU (1) | AU2013208536B2 (es) |
CA (1) | CA2861024C (es) |
DK (1) | DK2803662T3 (es) |
ES (1) | ES2626036T3 (es) |
HK (1) | HK1203191A1 (es) |
IL (1) | IL233592B (es) |
NZ (1) | NZ627878A (es) |
PL (1) | PL2803662T3 (es) |
PT (1) | PT2803662T (es) |
SG (2) | SG10201605325TA (es) |
WO (1) | WO2013105608A1 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2803662B1 (en) | 2012-01-13 | 2017-03-01 | Nippon Chemiphar Co., Ltd. | P2x4 receptor antagonist |
ES2753422T3 (es) * | 2013-07-12 | 2020-04-08 | Nippon Chemiphar Co | Antagonista de receptor P2X4 |
AU2014288116B2 (en) | 2013-07-12 | 2018-05-17 | Kyushu University | P2X4 receptor antagonist |
WO2015088565A1 (en) * | 2013-12-13 | 2015-06-18 | Sunovion Pharmaceuticals Inc. | P2x4 receptor modulating compounds and methods of use thereof |
EP3274336A4 (en) | 2015-03-24 | 2018-11-14 | Piramal Enterprises Limited | An improved process for the preparation of clobazam and its intermediate |
WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
ES2938341T3 (es) | 2016-03-07 | 2023-04-10 | Enanta Pharm Inc | Agentes antivirales contra la hepatitis B |
CA3022358A1 (en) | 2016-04-28 | 2017-11-02 | Nippon Chemiphar Co., Ltd. | Medicament for treatment of multiple sclerosis |
MA45020B1 (fr) | 2016-05-03 | 2020-11-30 | Bayer Pharma AG | Dérivés sulfonamides aromatiques |
WO2018104305A1 (en) | 2016-12-09 | 2018-06-14 | Bayer Pharma Aktiengesellschaft | Field of application of the invention |
WO2018104307A1 (en) | 2016-12-09 | 2018-06-14 | Bayer Pharma Aktiengesellschaft | Aromatic sulfonamide derivatives and their use as anatagon i sts or negative allosteric modulators of p2x4 |
WO2018210729A1 (en) | 2017-05-18 | 2018-11-22 | Bayer Pharma Aktiengesellschaft | Aromatic sulfonamide derivatives as antagonists or negative allosteric modulators of p2x4 receptor |
WO2019046271A1 (en) | 2017-08-28 | 2019-03-07 | Enanta Pharmaceuticals, Inc. | ANTIVIRAL AGENTS AGAINST HEPATITIS B |
WO2019143902A2 (en) | 2018-01-22 | 2019-07-25 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
WO2019177117A1 (ja) | 2018-03-14 | 2019-09-19 | 日本ケミファ株式会社 | 咳嗽の治療のための医薬 |
JPWO2020050253A1 (ja) * | 2018-09-03 | 2021-08-30 | 日本ケミファ株式会社 | 糖尿病性末梢神経障害のための医薬 |
MX2021003253A (es) | 2018-09-21 | 2021-08-11 | Enanta Pharm Inc | Heterociclos funcionalizados como agentes antivirales. |
AU2019385477A1 (en) | 2018-11-21 | 2021-06-10 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
WO2021007488A1 (en) | 2019-07-11 | 2021-01-14 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
EP4085056A1 (en) | 2020-01-03 | 2022-11-09 | Berg LLC | Polycyclic amides as ube2k modulators for treating cancer |
US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
CA3174216A1 (en) * | 2020-03-30 | 2021-10-07 | Luca ANTONIOLI | Medicament for preventing or treating irritable bowel syndrome or inflammatory bowel disease |
AU2021301158A1 (en) | 2020-06-30 | 2022-12-15 | Bayer Aktiengesellschaft | Use of N-phenylacetamides having P2X4 receptor antagonistic activity for treating certain ocular disorders |
WO2022002859A1 (en) | 2020-06-30 | 2022-01-06 | Bayer Aktiengesellschaft | Substituted n-phenylacetamides having p2x4 receptor antagonistic activity |
CN116437928A (zh) | 2020-08-03 | 2023-07-14 | 日本化学药品株式会社 | 用于预防、抑制或治疗伴随着过敏反应的症状的医药组合物 |
WO2022049253A1 (en) | 2020-09-07 | 2022-03-10 | Bayer Aktiengesellschaft | Substituted n-heteroaryl-n-pyridinylacetamides as p2x4 modulators |
CA3220039A1 (en) | 2021-06-14 | 2022-12-22 | Jr. David St. Jean | Urea derivatives which can be used to treat cancer |
IT202100025124A1 (it) | 2021-09-30 | 2023-03-30 | Univ Degli Studi Di Firenze | Medicamento per uso nel prevenire o trattare il dolore nocicettivo e/o viscerale |
CA3233194A1 (en) | 2021-09-30 | 2023-04-06 | Toshiyasu Imai | Agent for preventing or treating respiratory disease |
WO2023157895A1 (ja) * | 2022-02-17 | 2023-08-24 | 国立大学法人 鳥取大学 | 子宮内膜症又は子宮腺筋症の予防又は治療剤 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5534960Y2 (es) | 1977-01-31 | 1980-08-18 | ||
JPS53111093A (en) * | 1977-03-07 | 1978-09-28 | Takeda Chem Ind Ltd | Imidazo(1,5-d)(1,4)benzodiazepin derivative and its preparation |
JPH02304437A (ja) | 1989-05-19 | 1990-12-18 | Konica Corp | 新規な写真用カプラー |
HUT76135A (en) * | 1994-04-14 | 1997-06-30 | Glaxo Wellcome Inc | Cholecystokinin and gastrin modulating 5-heterocyclic-1,5-benzodiazepines |
PE27497A1 (es) * | 1994-04-15 | 1997-08-07 | Glaxo Inc | Derivados de 1,5 benzodiazepina |
SE0104250D0 (sv) | 2001-12-14 | 2001-12-14 | Astrazeneca Ab | Heterocyclic compounds |
US20060128695A1 (en) * | 2002-10-30 | 2006-06-15 | Neuro3D | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
DE10312969A1 (de) * | 2003-03-24 | 2004-10-07 | Bayer Healthcare Ag | Benzofuro-1,4-diazepin-2-on-Derivate |
US20050074819A1 (en) | 2003-10-01 | 2005-04-07 | Japan Health Sciences Foundation | Screening method of drug for treatment of neuropathic pain |
KR100512749B1 (ko) | 2004-01-14 | 2005-09-07 | 삼성전자주식회사 | 모니터장치 |
US20100298285A1 (en) | 2006-03-16 | 2010-11-25 | Kelly Michael G | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof |
JPWO2008023847A1 (ja) | 2006-08-25 | 2010-01-14 | 日本ケミファ株式会社 | P2x4受容体拮抗剤 |
RS53042B (en) | 2007-02-16 | 2014-04-30 | Merrimack Pharmaceuticals Inc. | ANTIBODIES AGAINST ERBB3 AND THEIR USES |
JP2012087053A (ja) * | 2009-02-03 | 2012-05-10 | Nippon Chemiphar Co Ltd | ジアゼピンジオン誘導体 |
CN102395577B (zh) | 2009-02-16 | 2014-04-23 | 日本化学医药株式会社 | 二氮杂*二酮衍生物 |
KR101890441B1 (ko) * | 2010-07-13 | 2018-08-21 | 닛뽕 케미파 가부시키가이샤 | P2x4 수용체 길항제 |
JP2013209292A (ja) * | 2010-07-23 | 2013-10-10 | Nippon Chemiphar Co Ltd | P2x4受容体拮抗剤 |
JP6325252B2 (ja) * | 2011-05-25 | 2018-05-16 | 国立大学法人九州大学 | ギラン・バレー症候群に伴う神経因性疼痛の予防又は治療剤 |
EP2803662B1 (en) | 2012-01-13 | 2017-03-01 | Nippon Chemiphar Co., Ltd. | P2x4 receptor antagonist |
-
2013
- 2013-01-10 EP EP13736295.0A patent/EP2803662B1/en active Active
- 2013-01-10 SG SG10201605325TA patent/SG10201605325TA/en unknown
- 2013-01-10 KR KR1020207007764A patent/KR102140746B1/ko active IP Right Grant
- 2013-01-10 PT PT137362950T patent/PT2803662T/pt unknown
- 2013-01-10 CN CN201810753396.5A patent/CN108863959B/zh active Active
- 2013-01-10 KR KR1020147022599A patent/KR102092147B1/ko active IP Right Grant
- 2013-01-10 WO PCT/JP2013/050320 patent/WO2013105608A1/ja active Application Filing
- 2013-01-10 CN CN201910768337.XA patent/CN110483423A/zh active Pending
- 2013-01-10 JP JP2013553310A patent/JP6207399B2/ja active Active
- 2013-01-10 NZ NZ627878A patent/NZ627878A/en unknown
- 2013-01-10 PL PL13736295T patent/PL2803662T3/pl unknown
- 2013-01-10 ES ES13736295.0T patent/ES2626036T3/es active Active
- 2013-01-10 US US14/371,868 patent/US9382236B2/en active Active
- 2013-01-10 DK DK13736295.0T patent/DK2803662T3/en active
- 2013-01-10 CN CN201380005473.4A patent/CN104066724B/zh active Active
- 2013-01-10 AU AU2013208536A patent/AU2013208536B2/en active Active
- 2013-01-10 SG SG11201404030YA patent/SG11201404030YA/en unknown
- 2013-01-10 CN CN202010213899.0A patent/CN111333588A/zh active Pending
- 2013-01-10 CA CA2861024A patent/CA2861024C/en active Active
-
2014
- 2014-07-10 IL IL233592A patent/IL233592B/en active IP Right Grant
-
2015
- 2015-04-15 HK HK15103643.8A patent/HK1203191A1/xx unknown
-
2016
- 2016-06-08 US US15/176,857 patent/US9969700B2/en active Active
-
2018
- 2018-03-16 US US15/923,685 patent/US10633349B2/en active Active
-
2020
- 2020-03-23 US US16/826,877 patent/US11434207B2/en active Active
-
2022
- 2022-07-22 US US17/871,201 patent/US20220380322A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1203191A1 (en) | P2x4 receptor antagonist p2x4 | |
HK1211039A1 (en) | Engineering -cell receptors | |
HK1252279A1 (zh) | 5- ht3受體拮抗劑 | |
GB201213700D0 (en) | Receptor antagnists II | |
EP2911675A4 (en) | 2-PYRIDYLOXY-3-SUBSTITUTED 4-NITRIL-OREXINE RECEPTOR ANTAGONISTS | |
EP2934527A4 (en) | ANTAGONIST 2-PYRYDYLOXY-4-ESTER COMPOUNDS OF OREXIN RECEPTORS | |
EP2934516A4 (en) | ANTAGONISTS OF 3-ESTER-4-SUBSTITUTED OREXIN RECEPTORS | |
EP2925321A4 (en) | 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists | |
EP2934517A4 (en) | 4-SUBSTITUTED 2-PYRYDYLOXY-3-NITRILE OREXIN RECEPTOR ANTAGONISTS | |
EP2908812A4 (en) | 2-pyridyloxy, 3-ESTER-4-NITRILOREXIN receptor antagonists | |
EP3020707A4 (en) | ANTAGONIST OF P2X4 RECEPTORS | |
EP3020717A4 (en) | P2x4 receptor antagonist | |
EP2665707A4 (en) | Mineralocorticoid receptor antagonists | |
EP2619204A4 (en) | TRIAZOLOPYRAZINONES AS ANTAGONISTS OF P2X7 RECEPTORS | |
EP2765860A4 (en) | Mineralocorticoid receptor antagonists | |
HK1192228A1 (zh) | 受體拮抗劑 | |
EP2617717A4 (en) | ANTAGONIST OF P2X4 RECEIVER | |
HK1205104A1 (en) | Novel neurokinin receptor antagonist compounds | |
EP2697203A4 (en) | ANTAGONISTS OF MINERALOCORTICOID RECEPTORS | |
EP2874621A4 (en) | Mineralocorticoid receptor antagonists | |
EP2765859A4 (en) | Mineralocorticoid receptor antagonists | |
EP2765858A4 (en) | ANTAGONISTS OF A MINERALOCORTICOID RECEPTOR | |
GB201223053D0 (en) | Receptor | |
GB201213698D0 (en) | Receptor antagonists II | |
GB201213699D0 (en) | Receptor antagonists II |